biostudies-literatureSolimando AGAssociazione Italiana per la Ricerca sul CancroRegione PugliaUniversità degli Studi di Bari Aldo Moro65-74https://www.ebi.ac.uk/biostudies/studies/S-EPMC8863772biostudies-literatureUnknown22(1)<h4>Background & aims</h4>A plethora of second-line therapies have been recently introduced for hepatocellular carcinoma (HCC) treatment with promising results. A meta-analysis of second-line treatments for HCC has been performed to better tailor their use based on improved patient stratification and to identify the best available option.<h4>Methods</h4>Pubmed, Scopus, Web of Science, and ClinicalTrials.gov were searched for randomized controlled trials evaluating second-line treatment for advanced HCC in patients already treated with sorafenib. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS) and drug withdrawal due to adverse events. Network meta-analyses were performed considering placebo as the basis for comparison in efficacy and sClinical and experimental medicineSecond-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.PMC886377220441De Re VKrebs MNanni OVacca APetracci EFasano RArgentiero ABrunetti OSolimando AGSusca NRacanelli VAzzali ISilvestris NLeone PfalseSecond-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.<h4>Background & aims</h4>A plethora of second-line therapies have been recently introduced for hepatocellular carcinoma (HCC) treatment with promising results. A meta-analysis of second-line treatments for HCC has been performed to better tailor their use based on improved patient stratification and to identify the best available option.<h4>Methods</h4>Pubmed, Scopus, Web of Science, and ClinicalTrials.gov were searched for randomized controlled trials evaluating second-line treatment for advanced HCC in patients already treated with sorafenib. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS) and drug withdrawal due to adverse events. Network meta-analyses were performed considering placebo as the basis for comparison in efficacy and s2022-01-01T00:00:00Z2022 Feb2026-06-19T04:51:28.59Z2025-02-19T03:26:19.325ZS-EPMC88637723414619610.1007/s10238-021-00727-7